Why Is COGENT BIOSCIENCES I (COGT) Stock Down Today?
By the Top Tier Newswire AI Desk · reviewed against 6 wire stories
COGENT BIOSCIENCES I (COGT) is down -5.51% in the latest session. Our newswire has captured 6 stories on COGT across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for COGT publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
COGT · today's session (5-min) · -5.05% vs prior close · updated 11:52 AM ETAI sentiment, last 36h · averaged over 6 stories · 54/100 neutral
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
17h agoTipRanksBEARISH 28General
Cogent Biosciences Announces $400 Million ATM Offering
An update from Cogent Biosciences ( ($COGT) ) is now available. On August 10, 2026, Cogent Biosciences filed a prospectus supplement with the U.S. Securities and Ex...
18h agoSEC 8-KNEUTRAL 50General
Cogent Biosciences, Inc. (COGT) files 8-K
Filed: 2026-08-10 AccNo: 0001193125-26-342695 Size: 155 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
1d agoMarketChameleonBULLISH 73Product/PR
Cogent Biosciences Achieves Key Milestones with Bezuclastinib, Maintains Strong Cash Position Through 2028
August 10, 2026
Cogent Biosciences reaches pivotal regulatory and clinical milestones with bezuclastinib for GIST and systemic mastocytosis, supported by a solid cash runway. Detailed Phase 3 results show significant clinical benefit, corporate expansion is underway, and multiple new drug applications are progressing.
1d agoSeeking AlphaNEUTRAL 50Earnings
Cogent Biosciences reports Q2 results
1d agoSEC 8-KNEUTRAL 50General
Cogent Biosciences, Inc. (COGT) files 8-K
Filed: 2026-08-10 AccNo: 0001193125-26-341315 Size: 375 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
1d agoBusiness InsiderBULLISH 73Product/PR
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30
Frequently asked questions
Why is COGT stock down today?
COGENT BIOSCIENCES I (COGT) is down -5.51% in the latest session. Our newswire has captured 6 stories on COGT across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100). The most recent driver: "Cogent Biosciences Announces $400 Million ATM Offering" (TipRanks).
Is COGT a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of COGT coverage reads 54/100 over 6 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →